Olema Pharmaceuticals, Inc. OLMA

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
48/100
Developing

Ranked against 712 peers in Biotechnology

About Olema Pharmaceuticals, Inc.

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative … Full OLMA analysis →

Key strengths

  • Strong Liquidity Buffer Liquidity position is strong (score 0.79), providing operational cushion.

Key risks

  • Elevated Debt Risk Debt serviceability is weak (score 0.23), raising refinancing risk.
  • Weak or Negative Cash Flow Cash generation is weak (score 0.00), limiting financial flexibility.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Insufficient Data
—
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where OLMA ranks in Biotechnology

Olema Pharmaceuticals, Inc. ranks #269 of 713 scored companies in Biotechnology by moat score — the top 38%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
265 MBX Biosciences, Inc. MBX 48/100 Developing
266 Disc Medicine, Inc. IRON 48/100 Developing
267 Monopar Therapeutics Inc. MNPR 48/100 Developing
268 Intellia Therapeutics, Inc. NTLA 48/100 Developing
269 Olema Pharmaceuticals, Inc. OLMA 48/100 Developing
270 Kymera Therapeutics, Inc. KYMR 47/100 Developing
271 LENZ Therapeutics, Inc. LENZ 47/100 Developing
272 Moderna, Inc. MRNA 47/100 Developing
273 Relmada Therapeutics, Inc. RLMD 47/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How OLMA scores on the Corporate Default defenses

Pricing Power

Not measurable · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Not measurable · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Not measurable · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 50 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 44 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Not measurable · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding OLMA's moat

What is Olema Pharmaceuticals, Inc.'s moat score?

Olema Pharmaceuticals, Inc. (OLMA) scores 48 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #269 of 713 scored companies in Biotechnology, the top 38%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Capital Efficiency (50/100) and its weakest is Resilience (44/100).

How does Olema Pharmaceuticals, Inc. compare with other Biotechnology companies?

Olema Pharmaceuticals, Inc. ranks #269 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Intellia Therapeutics, Inc. (NTLA) at 48 just above it and Kymera Therapeutics, Inc. (KYMR) at 47 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Olema Pharmaceuticals, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Olema Pharmaceuticals, Inc.?

The Corporate Default template measures 6 defenses, and OLMA scores: Pricing Power (not measurable), Cost Advantage (not measurable), Customer Stickiness (not measurable), Capital Efficiency (50), Resilience (44), Scale & Market Position (not measurable). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000